DAFTAR PUSTAKA

Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Balmey RW, Robertson JFR, Nicholson RI, et al. (2004). Expression of luminal and basal cytokeratins in human breast carcinoma. J. Pathol. 203:(2) 661–671.

Abdelrahman AE, Rashed HE, Abdelgawad M, Abdelhamid MI (2017). Prognostic impact of EGFR and cytokeratin 5/6 immunohistochemical expression in triple-negative breast cancer. Ann. Diagn. Pathol. 2843–53. Available at: http://dx.doi.org/10.1016/j.anndiagpath.2017.01.009

Abramson VG, Lehmann BD, Ballinger TJ, Pietenpol JA (2015). Subtyping of triple-negative breast cancer: Implications for therapy. Cancer 121:(1) 8–16.

Ali R, Wendt MK (2017). The paradoxical functions of EGFR during breast cancer progression. Signal Transduct. Target. Ther. 2:(December 2016) 1–7. Available at: http://dx.doi.org/10.1038/sigtrans.2016.42

Anders CK, Carey LA (2009). Biology , Metastatic Patterns , and Treatment of Patients with Triple-Negative Breast Cancer. Clin. Breast Cancer 9:(June) S73–S81. Available at: http://dx.doi.org/10.3816/CBC.2009.s.008

de Azambuja E, Cardoso F, de Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, et al. (2007). Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients. Br. J. Cancer 96:(10) 1504–1513. Available at: http://www.nature.com/articles/6603756

Badowska-Kozakiewicz AM, Budzik MP (2016). Immunohistochemical characteristics of basal-like breast cancer. Contemp Oncol (Pozn) 20:(6) 436–443.

Banerjee S (2006). Basal-like breast carcinomas: clinical outcome and response to chemotherapy. J. Clin. Pathol. 59:(7) 729–735. Available at: http://jcp.bmj.com/cgi/doi/10.1136/jcp.2005.033043

Blamey RW, Ellis IO, Pinder SE, Lee AHS, Macmillan RD, Morgan DAL, Robertson JFR, et al. (2007). Survival of invasive breast cancer according to the Nottingham Prognostic Index in cases diagnosed in 1990-1999. Eur. J. Cancer 43:(10) 1548–1555.

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA. Cancer J. Clin. 68:(6) 394–424.

Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, Jakubowicz J, et al. (2014). Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res. Treat. 147:(2) 401–405.

Cakir A, Gonul II, Uluoglu O (2012). A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas. Diagn. Pathol. 7:(1) 145. Available at: https://diagnosticpathology.biomedcentral.com/articles/10.1186/1746-1596-7-145.

Cheang MCU, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou CM, et al. (2008). Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype. Clin. Cancer Res. 14:(5) 1368–1376.

Cheang MCU, Voduc KD, Tu D, Jiang S, Leung S, Chia SK, Shepherd LE, et al. (2012). Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial. Clin. Cancer Res. 18:(8) 2402–2412.

Collignon J, Lousberg L, Schroeder H, Jerusalem G (2016). Triple-negative breast cancer: Treatment challenges and solutions. Breast Cancer Targets Ther. 893–107.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, et al. (2014). Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet 384:(9938) 164–172.

Denduluri N, Somerfield MR, Eisen A, Holloway JN, Hurria A, King TA, Lyman GH, et al. (2016). Selection of optimal adjuvant chemotherapy regimens for human epidermal growth factor receptor 2 (HER2) -negative and adjuvant targeted therapy for HER2-positive breast cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer C. J. Clin. Oncol. 34:(20) 2416–2427.

Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA (2009). Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res. Treat. 115:(2) 423–428.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, et al. (2007). Triple-negative breast cancer: Clinical features and patterns of recurrence. Clin. Cancer Res. 13:(15) 4429–4434.

Dogra A, Mehta A, Doval DC (2020). Are Basal-Like and Non-Basal-Like Triple-Negative Breast Cancers Really Different? J. Oncol. 20201–9. Available at: https://www.hindawi.com/journals/jo/2020/4061063/

Dogu GG, Ozkan M, Ozturk F, Dikilitas M, Er O, Ozturk A (2010). Triple-negative breast cancer: Immunohistochemical correlation with basaloid markers and prognostic value of survivin. Med. Oncol. 27:(1) 34–39.

Dreyer G, Vandorpe T, Smeets A, Forceville K, Brouwers B, Neven P, Janssens H, et al. (2013). Triple negative breast cancer: Clinical characteristics in the different histological subtypes. The Breast 22:(5) 761–766. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0960977613000118

Du F, Wang W, Wang Y, Li M, Zhu A, Wang J, Cai R, et al. (2020). Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer. Breast Cancer Res. Treat. 182:(1) 67–77. Available at: http://link.springer.com/10.1007/s10549-020-05648-9

Ellis IO, Lee AHS, Pinder SE, Rakha EA (2020). Tumors of the Breast. In CDM Fletcher, editor Diagnostic Histopathology of Tumors. Piladelphia: Elsevier, hal. 1119–1210.

Fan L, Goss PE, Strasser-Weippl K (2015). Current Status and Future Projections of Breast Cancer in Asia. Breast Care 10:(6) 372–378. Available at: https://www.karger.com/Article/FullText/441818

Fong Y, Evans J, Brook D, Kenkre J, Jarvis P, Gower-Thomas K (2015). The Nottingham Prognostic Index: Five- and ten-year data for all-cause survival within a screened population. Ann. R. Coll. Surg. Engl. 97:(2) 137–139.

Foulkes W, Smith I, Reis-Filho JS (2010). Triple-Negative Breast Cancer. N. Engl. J. Med. 3631938–1948.

Gadi VK, Davidson NE (2017). Practical Approach to Triple-Negative Breast Cancer. J. Oncol. Pract. 13:(5) 293–300.

Gangi A, Chung A, Mirocha J, Liou DZ, Leong T, Giuliano AE (2014). Breast-conserving therapy for triple-negative breast cancer. JAMA Surg. 149:(3) 252–258.

Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U, Harbeck N (2009). Triple-negative breast cancer - Current status and future directions. Ann. Oncol. 20:(12) 1913–1927.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011). Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann. Oncol. 22:(8) 1736–1747.

Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, et al. (2010). American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J. Clin. Oncol. 28:(16) 2784–2795.

Hashmi AA, Naz S, Hashmi SK, Hussain ZF, Irfan M, Bakar SMA, Faridi N, et al. (2018). Cytokeratin 5/6 and cytokeratin 8/18 expression in triple negative breast cancers: Clinicopathologic significance in South-Asian population. BMC Res. Notes 11:(1) 1–8. Available at: https://doi.org/10.1186/s13104-018-3477-4

Hashmi AA, Naz S, Hashmi SK, Irfan M, Hussain ZF, Khan EY, Asif H, et al. (2019). Epidermal growth factor receptor (EGFR) overexpression in triple-negative

66

breast cancer: association with clinicopathologic features and prognostic parameters. Surg. Exp. Pathol. 2:(1) 1–7.

Haybittle JL, Blamey RW, Elston CW, Johnson J, Doyle PJ, Campbell FC, Nicholson RI, et al. (1982). A prognostic index in primary breast cancer. Br. J. Cancer 45:(3) 361–366.

Huo D, Ikpatt F, Khramtsov A, Dangou JM, Nanda R, Dignam J, Zhang B, et al. (2009). Population differences in breast cancer: Survey in indigenous african women reveals over-representation of triple-negative breast cancer. J. Clin. Oncol. 27:(27) 4515–4521.

Ilie SM, Bacinschi XE, Botnariuc I, Anghel RM (2018). Potential clinically useful prognostic biomarkers in triple-negative breast cancer: Preliminary results of a retrospective analysis. Breast Cancer Targets Ther. 10177–194.

Inanc M, Ozkan M, Karaca H, Berk V, Bozkurt O, Duran AO, Ozaslan E, et al. (2014). Cytokeratin 5/6, c-Met expressions, and PTEN loss prognostic indicators in triple-negative breast cancer. Med. Oncol. 31:(1) .

James M, Dixit A, Robinson B, Frampton C, Davey V (2019). Outcomes for Patients with Non-metastatic Triple-negative Breast Cancer in New Zealand. Clin. Oncol. 31:(1) 17–24. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0936655518304424.

Al Jarroudi O, Abda N, Seddik Y, Brahmi SA, Afqir S (2017). Overweight: Is it a prognostic factor in women with triple-negative breast cancer? Asian Pacific J. Cancer Prev. 18:(6) 1519–1523.

Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, McIntyre KJ, et al. (2006). Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J. Clin. Oncol. 24:(34) 5381–5387.

Kaplan HG, Malmgren JA (2008). Impact of Triple Negative Phenotype on Breast Cancer Prognosis. Breast J. 14:(5) 456–463. Available at: http://doi.wiley.com/10.1111/j.1524-4741.2008.00622.x.

Karatas F, Erdem GU, Sahin S, Aytekin A, Yuce D, Sever AR, Babacan T, et al. (2017). Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients. Breast 32237–244. Available at: http://dx.doi.org/10.1016/j.breast.2016.05.013.

Keam B, Im S-A, Lee K-H, Han S-W, Oh D-Y, Kim JH, Lee S-H, et al. (2011). Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res. 13:(2) R22. Available at: https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr2834.

Kindts I, Buelens P, Laenen A, Van Limbergen E, Janssen H, Wildiers H, Weltens C (2017). Omitting radiation therapy in women with triple-negative breast cancer leads to worse breast cancer-specific survival. Breast 3218–25. Available at: http://dx.doi.org/10.1016/j.breast.2016.12.007.

Kumar P, Aggarwal R (2016). An overview of triple-negative breast cancer. Arch. Gynecol. Obstet. 293:(2) 247–269.

Kumar S, Furrukh M, Al-Baimani K, Al-Ajmi A, Burney IA, Al-Moundhri MS (2019). Outcomes of Women with Non-Metastatic Triple-Negative Breast Cancer in Oman: A single-centre experience. Sultan Qaboos Univ. Med. J. [SQUMJ] 19:(3) 209. Available at: https://journals.squ.edu.om/index.php/squmj/article/view/3312.

Kutomi G, Ohmura T, Suzuki Y, Kameshima H, Shima H, Takamaru T, Satomi F, et al. (2012). Clinicopathological Characteristics of Basal Type Breast Cancer in Triple-Negative Breast Cancer. J. Cancer Ther. 03:(05) 836–840.

Kwon J, Eom KY, Koo TR, Kim BH, Kang E, Kim SW, Kim YJ, et al. (2017). A prognostic model for patients with triple-negative breast cancer: Importance of the modified nottingham prognostic index and age. J. Breast Cancer 20:(1) 65–73.

Lachapelle J, Foulkes WD (2011). Triple-negative and basal-like breast cancer:Implications for oncologists. Curr. Oncol. 18:(4) 161–164.

Lakatos E (1988). Sample sizes based on the log-rank statistic in complex clinical trials. Biometrics 44:(1) 229–41. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3358991.

Lehmann BD, Shyr Y, Pietenpol JA, Lehmann BD, Bauer JA, Chen X, Sanders ME, et al. (2011). Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest. 121:(7) 2750–2767.

Leidy J, Khan A, Kandil D (2014). Basal-like breast cancer: Update on clinicopathologic, immunohistochemical, and molecular features. Arch. Pathol. Lab. Med. 138:(1) 37–43.

Leong SPL, Shen Z-Z, Liu T-J, Agarwal G, Tajima T, Paik N-S, Sandelin K, et al. (2010). Is Breast Cancer the Same Disease in Asian and Western Countries? World J. Surg. 34:(10) 2308–2324. Available at: http://link.springer.com/10.1007/s00268-010-0683-1.

Liedtke C, Hess KR, Karn T, Rody A, Kiesel L, Hortobagyi GN, Pusztai L, et al. (2013). The prognostic impact of age in patients with triple-negative breast cancer. Breast Cancer Res. Treat. 138:(2) 591–599.

Liu M, Mo Q-G, Wei C-Y, Qin Q-H, Huang Z, He J (2013). Platinum-based chemotherapy in triple-negative breast cancer: A meta-analysis. Oncol. Lett. 5:(3)

983–991. Available at: https://www.spandidos-publications.com/10.3892/ol.2012.1093.

Liu YX, Wang KR, Xing H, Zhai XJ, Wang LP, Wang W (2016). Attempt towards a novel classification of triple-negative breast cancer using immunohistochemical markers. Oncol. Lett. 12:(2) 1240–1256.

Lowery AJ, Kell MR, Glynn RW, Kerin MJ, Sweeney KJ (2012). Locoregional recurrence after breast cancer surgery: A systematic review by receptor phenotype. Breast Cancer Res. Treat. 133:(3) 831–841.

Ludwik KA, Campbell JP, Li M, Li Y, Sandusky ZM, Pasic L, Sowder ME, et al. (2016). Development of a RSK Inhibitor as a Novel Therapy for Triple-Negative Breast Cancer. Mol. Cancer Ther. 15:(11) 2598–2608. Available at: http://mct.aacrjournals.org/cgi/doi/10.1158/1535-7163.MCT-16-0106

Maeda T, Nakanishi Y, Hirotani Y, Fuchinoue F, Enomoto K, Sakurai K, Amano S, et al. (2016). Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer. Med. Mol. Morphol. 49:(1) 11–21.

Midgley R, Kerr DJ (2009). Capecitabine: Have we got the dose right? Nat. Clin. Pract. Oncol. 6:(1) 17–24.

Milioli HH, Tishchenko I, Riveros C, Berretta R, Moscato P (2017). Basal-like breast cancer: molecular profiles, clinical features and survival outcomes. BMC Med. Genomics 10:(1) 19. Available at: https://bmcmedgenomics.biomedcentral.com/articles/10.1186/s12920-017-0250-9.

Von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, et al. (2014). Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial. Lancet Oncol. 15:(7) 747–756.

Nahed AS, Shaimaa MY (2016). Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol. Med. 13:(4) 496. Available at: http://www.cancerbiomed.org/index.php/cocr/article/view/994.

Najafi S, Mozaffari HR, Sadeghi M (2017). Clinicopathological Features of Non-metastatic Triple Negative Breast Cancer. Iran. J. Blood Cancer 9:(1) 18–23.

NCSS (2017). PASS 15 Power Analysis and Sample Size Software. Available at: ncss.com/software/pass.

Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, et al. (2004). Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin. Cancer Res. 10:(16) 5367–5374.

Nogi H, Kobayashi T, Suzuki M, Tabei I, Kawase K, Toriumi Y, Fukushima H, et al. (2009). EGFR as paradoxical predictor of chemosensitivity and outcome among triple-negative breast cancer. Oncol. Rep. 21413–417.

van der Noord VE, McLaughlin RP, Smid M, Foekens JA, Martens JWM, Zhang Y, van de Water B (2019). An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer. Sci. Rep. 9:(1) 13308. Available at: http://www.nature.com/articles/s41598-019-49809-3.

Ovcaricek T, Frkovic S, Matos E, Mozina B, Borstnar S (2011). Triple negative breast cancer - prognostic factors and survival. Radiol. Oncol. 45:(1) . Available at: https://content.sciendo.com/doi/10.2478/v10019-010-0054-4.

Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF (2019). Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer 19:(1) 1065. Available at: https://bmccancer. biomedcentral.com/articles/10.1186/s12885-019-6253-5.

Park H, Jang M, Kim E, Kim H, Lee H, Kim Y, Kim J, et al. (2014). High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 27:(9) 1212–1222. Available at: http://www.nature.com/articles/modpathol 2013251.

Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, Kim JH, et al. (2014). High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod. Pathol. 27:(9) 1212–1222. Available at: http://dx.doi.org/10.1038/modpathol. 2013.251.

Park JH, Ahn J-H, Kim S-B (2018). How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. ESMO Open 3:(Suppl 1) e000357. Available at: http://esmoopen.bmj .com/lookup/doi/10.1136/esmoopen-2018-000357

Perou CM (2011). Molecular Stratification of Triple-Negative Breast Cancers. Oncologist 16:(Supplement 1) 61–70.

Phung MT, Tin Tin S, Elwood JM (2019). Prognostic models for breast cancer: A systematic review. BMC Cancer 19:(1) 1–18.

Pillai SKK, Tay A, Nair S, Leong CO (2012). Triple-negative breast cancer is associated with EGFR, CK5/6 and c-KIT expression in Malaysian women. BMC Clin. Pathol. 12:(1) 1. Available at: BMC Clinical Pathology

Plasilova ML, Hayse B, Killelea BK, Horowitz NR, Chagpar AB, Lannin DR (2016). Features of triple-negative breast cancer. Medicine (Baltimore). 95:(35) e4614. Available at: http://journals.lww.com/00005792-201608300-00038

Primadanti SJ, Setiawan IGB (2018). Prevalensi kanker payudara subtipe triple negative pada wanita usia muda di Bali periode januari 2014 – oktober 2016. E-

Jurnal Med. 7:(2) 87–90. Available at: https://ojs.unud.ac.id/index.php/eum/article/download/37428/22738.

Purwanto, I. (2020). Perbandingan Kesintasan Hidup Pasien Kanker Payudara Triple-negative yang Mendapatkan Kemoterapi Adjuvan Berbasis Antrasiklin dan Platinum : Kajian P53, TILs, PDL-1,mTOR,miRNA-200c, miRNA-223, dan miRNA-21 terhadap Kesintasan Hidup Pasien Kanker Payudara Triple-Negatif sebagai Biomarker Prognostik. Disertasi. Program Doktor Ilmu Kedokteran & Kesehatan. Fakultas Kedokteran, Kesehatan Masyarakat dan Keperawatan, Universitas Gadjah Mada, Yogyakarta.

Santa-Maria CA (2020). Advances in Neoadjuvant and Adjuvant Therapy for Breast Cancer. In AM Cameron dan JL Cameron, editor Current Surgical Therapy. Philadelphia: Elsevier, hal. 702–706.

Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, et al. (2015). Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A. J. Clin. Oncol. 33:(1) 13–21.

Skandan SP (2016). 5 year Overall survival of triple negative breast cancer: A single institution experience. J. Clin. Oncol. 34:(15_suppl) e12580–e12580. Available at: http://ascopubs.org/doi/10.1200/JCO.2016.34.15_suppl.e12580.

Sultana R, Kataki AC, Barthakur BB, Sarma A, Bose S (2020). Clinicopathological and immunohistochemical characteristics of breast cancer patients from Northeast India with special reference to triple negative breast cancer: A prospective study. Curr. Probl. Cancer100556. Available at: https://linkinghub.elsevier.com/retrieve/pii/S0147027220300295.

Tan AR (2018). Triple-Negative Breast Cancer A Clinician's Guide. AR Tan, editor. Switzerland: Springer International Publishing.

Tan T, Dent R (2018). Triple-Negative Breast Cancer: Clinical Features. In Triple-Negative Breast Cancer. Cham: Springer International Publishing, hal. 23–32. Available at: http://link.springer.com/10.1007/978-3-319-69980-6_2.

Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH (2010). Triple-negative breast cancer: Clinicopathological characteristics and relationship with basal-like breast cancer. Mod. Pathol. 23:(1) 123–133. Available at: http://dx.doi.org/10.1038/modpathol.2009.145.

Toyama T, Yamashita H, Kondo N, Okuda K, Takahashi S, Sasaki H, Sugiura H, et al. (2008). Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers. BMC Cancer 81–12.

Uscanga-Perales GI, Santuario-Facio SK, Ortiz-López R (2016). Triple negative breast cancer: Deciphering the biology and heterogeneity. Med. Univ. 18:(71) 105–114. Available at: http://dx.doi.org/10.1016/j.rmu.2016.05.007.

Vetter M, Fokas S, Biskup E, Schmid T, Schwab F, Schoetzau A, Güth U, et al. (2017). Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: A single center experience. Oncotarget 8:(43) 75617–75626.

Viale G, Rotmensz N, Maisonneuve P, Bottiglieri L, Montagna E, Luini A, Veronesi P, et al. (2009). Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: Prognostic implications of EGFR immunoreactivity. Breast Cancer Res. Treat. 116:(2) 317–328.

Vora H, Parikh S, Patel N (2019). Immunohistochemical Characterisation of Basal Like Phenotype of Triple Negative Breast Cancer from Western India. Int. J. Res. Rev. 6:(10) 1–8.

Wang C, Kar S, Lai X, Cai W, Arfuso F, Sethi G, Lobie PE, et al. (2018). Triple negative breast cancer in Asia: An insider's view. Cancer Treat. Rev. 6229–38. Available at: https://doi.org/10.1016/j.ctrv.2017.10.014.

Wang R-X, Chen S, Jin X, Shao Z-M (2016). Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin. Sci. Rep. 6:(1) 30091. Available at: http://www.nature.com/articles/srep30091.

Widodo I, Dwianingsih E, Aryandono T, Soeripto S (2019). Clinicopathological Characteristic and Prognostic Significance of Indonesian Triple Negative Breast Cancer. Indones. Biomed. J. 11:(3) 225–337. Available at: https://inabj.org/index.php/ibj/article/view/831.

Wisinski KB, Tevaarwerk AJ, O'Regan RM (2018). Endocrine Therapy for Breast Cancer. In KI Bland, EM Copeland, VS Klimberg, dan WJ Gradishar, editor The Breast: Comprehensive Management of Benign and Malignant Diseases. Piladelphia: Elsevier, hal. 907–923.

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett MS, Bilous M, et al. (2018). Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : American Society of Clinical Oncology / College of American Pathologists Clinical Practice Guideline Focused Update. J. Clin. Oncol. 36:(20) 2105–2122.

Wu Q, Ma G, Deng Y, Luo W, Zhao Y, Li W, Zhou Q (2019). Prognostic value of ki-67 in patients with resected triple-negative breast cancer: A meta-analysis. Front. Oncol. 9:(OCT) 1–9.

Yadav BS, Chanana P, Jhamb S (2015). Biomarkers in triple negative breast cancer: A review. World J. Clin. Oncol. 6:(6) 252–263.

Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H (2009). Clinical significance of basal-like subtype in triple-negative breast cancer. In Breast Cancer. hal. 260–267.

Yeh J, Chun J, Schwartz S, Wang A, Kern E, Guth AA, Axelrod D, et al. (2017). Clinical Characteristics in Patients with Triple Negative Breast Cancer. Int. J. Breast Cancer 20171–5. Available at: https://www.hindawi.com/journals/ijbc/ 2017/1796145.

Yu K-D, Ye F-G, He M, Fan L, Ma D, Mo M, Wu J, et al. (2020). Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer. JAMA Oncol. Available at: https://jamanetwork.com/journals/ jamaoncology/fullarticle/2769305.

Yue Y, Astvatsaturyan K, Cui X, Zhang X, Fraa B, Bose S (2016). Stratification of prognosis of triple-negative breast cancer patients using combinatorial biomarkers. PLoS One 11:(3) 1–13.

Zhu X, Chen L, Huang B, Wang Y, Ji L, Wu J, Di G, et al. (2020). The prognostic and predictive potential of Ki-67 in triple-negative breast cancer. Sci. Rep. 10:(1) 225. Available at: http://www.nature.com/articles/s41598-019-57094-3